Breaking news on lymphoma, leukemia
Celgene Officially Notified Of ANDA Filing For REVLIMID(R) published
Mon, 06 Sep 2010 04:00:00 PDT
Celgene Corporation (NASDAQ: CELG) announced it has received a Paragraph IV Certification Letter advising that Natco Pharma Limited of Hyderabad, India, submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA)...
Acupuncture Helps Ease Side Effects And Symptoms Of Some Cancers published
Sun, 05 Sep 2010 00:00:00 PDT
Recent studies have shown that acupuncture can help control a number of symptoms and side effects -- such as pain, fatigue, dry mouth, nausea, and vomiting -- associated with a variety of cancers and their treatments...
Blood Publication Shows MLN4924 Preclinical Activity In Lymphoma published
Sun, 05 Sep 2010 00:00:00 PDT
Millennium: The Takeda Oncology Company announced the publication of an article in the journal Blood describing the novel mechanism of action of MLN4924 through targeted pathway modulation in diffuse large B-cell lymphoma (DLBCL). MLN4924 is a small molecule inhibitor of the NEDD8-Activating Enzyme (NAE), a key component of the protein homeostasis pathway...
Molecular Imaging's Benefits In The Evaluation And Successful Treatment Planning For A Wide Spectrum Of Diseases published
Fri, 03 Sep 2010 01:00:00 PDT
A series of studies published in the September Journal of Nuclear Medicine (JNM) show that molecular imaging plays a critical role in the evaluation and treatment planning for a broad spectrum of cancers, including thyroid cancer and lymphoma...
Novartis Drug Tasigna® Approved In Switzerland After Fast-track Review For Treatment Of Patients With Newly Diagnosed Ph+ CML published
Thu, 02 Sep 2010 03:00:00 PDT
The Swiss health authority Swissmedic has granted approval for Tasigna® (nilotinib) 300 mg twice daily for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase...
Taking Aim At Pre-Leukemia Disorders: NewYork-Presbyterian/Columbia Establishes Myelodysplastic Syndromes Center published
Tue, 31 Aug 2010 01:00:00 PDT
NewYork-Presbyterian Hospital/Columbia University Medical Center has established a new center devoted to research and treatment of pre-leukemia blood disorders. Known as the Myelodysplastic Syndromes Center, it is one of the largest programs of its kind in the nation. Myelodysplastic syndromes (MDS) are disorders interfering with blood production in the bone marrow...
LFB's Recombinant Anti-CD20 Monoclonal Antibody Is Granted Orphan Drug Status In The USA For Chronic Lymphocytic Leukemia published
Fri, 27 Aug 2010 01:00:00 PDT
The recombinant anti-CD20 monoclonal antibody produced by LFB Biotechnologies received orphan drug status for the treatment of Chronic Lymphocytic Leukemia (CLL). This approval from the FDA Office of Orphan Products Development was granted on August 6th, 2010. Chronic lymphocytic leukemia is the most common form of leukemia in the United States...
NICE Proposes To Restrict Access To Velcade(R) In Newly Diagnosed Multiple Myeloma Patients Janssen-Cilag To Challenge NICE Recommendation published
Fri, 27 Aug 2010 01:00:00 PDT
Janssen-Cilag is disappointed that recommendations from the National Institute for Health and Clinical Excellence (NICE) will limit patient access to Velcade (bortezomib) in newly diagnosed (front-line) multiple myeloma...
NICE Draft Guidance Recommends Bortezomib And Thalidomide For Multiple Myeloma published
Thu, 26 Aug 2010 06:00:00 PDT
In draft guidance published today (26 August 2010) NICE has recommended two treatments for multiple myeloma. Thalidomide (Thalidomide, Celgene) in combination with an alkylating agent and a corticosteroid is recommended for the first-line treatment of multiple myeloma in people for whom high-dose chemotherapy with stem cell transplantation is considered inappropriate...
CAS Chemistry Research Report, A Decade Later Human Genome Discoveries Spur Growth Of Cancer Treatments published
Wed, 25 Aug 2010 02:00:00 PDT
Today, leukemia patients who have struggled with cancer therapy resistance and intolerance will now have more options thanks to targeted drug therapy. Such new treatment options are due, in part, to a rapid increase in journal and patent publications following the discovery of Gleevec, as reported by Chemical Abstracts Service (CAS), the world's authority for chemical information...
Extensive Trial Confirms Benefits Of Early Steroid Withdrawal For Transplant Patients published
Wed, 25 Aug 2010 00:00:00 PDT
A University of Cincinnati (UC) analysis of 10 years of data from local kidney transplant patients shows that patients removed from a corticosteroid regimen shortly after surgery have better graft survival rates, better survival rates and fewer cardiovascular events than patients kept on the traditional regimen of long-term steroids...
EpiCept Corporation Receives Refusal To File Letter From US FDA On Ceplene New Drug Application published
Tue, 24 Aug 2010 00:00:00 PDT
EpiCept Corporation (Nasdaq and Nasdaq OMX Stockholm Exchange: EPCT) announced that it received a refusal to file letter from the U.S. Food and Drug Administration (FDA) on the New Drug Application (NDA) for Ceplene® (histamine dihydrochloride)...
Lawrence Medical Products Launches MoveAround™ IV Buggy For Kids - Toddler Age To Teen - Undergoing IV Therapy published
Thu, 19 Aug 2010 01:00:00 PDT
Lawrence Medical Products, a family-owned business conceived to help Autumn Lawrence, diagnosed with infant leukemia in 2005 at seven and a half months old, has announced the launch of the MoveAround™ IV Buggy...
Link Between Blood Stem Cell And Leukemia Illuminated In UCSF-Led Study published
Wed, 18 Aug 2010 00:00:00 PDT
A UCSF-led team has discovered at least one key reason why blood stem cells are susceptible to developing the genetic mutations that can lead to adult leukemia. Their finding also may explain, they say, why some other age-related hematological disorders develop...
EMEA Validates Cell Therapeutics, Inc.'s (CTI) Expanded Pixantrone Pediatric Investigation Plan (PIP) published
Tue, 17 Aug 2010 02:00:00 PDT
Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced that it has received notice that the European Medicines Agency ("EMEA") has validated the expanded Pediatric Investigation Plan ("PIP") that CTI filed in July for pixantrone for the treatment of relapsed or refractory, aggressive non-Hodgkin's lymphoma (NHL)...
Mesoblast Limited (ASX:MSB) On Track For Phase 3 Bone Marrow Transplant Trial Following Positive Meeting With United States FDA published
Mon, 16 Aug 2010 02:00:00 PDT
Australian regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today provided market guidance on its Phase 3 bone! marrow transplant program following a formal meeting with the! United States Food and Drug Administration (FDA)...
Technique To Preserve Fertility In Young Women May Be Unsafe For Patients With Leukemia published
Sat, 14 Aug 2010 01:00:00 PDT
Although the use of ovarian tissue cryopreservation and transplantation has lead to 13 live births in women with lymphoma or solid tumors, this method of fertility preservation may be unsafe for patients with leukemia, according to a recent study published online in Blood, the journal of the American Society of Hematology...
Understanding How Blood Stem Cells Are Maintained Within The Niche Offers New Opportunities To Exploit Them Therapeutically published
Sat, 14 Aug 2010 00:00:00 PDT
Hematopoietic stem cells (HSCs) have two unique abilities that are prized by medical researchers: to self-renew and to develop into any kind of blood cell, which enables them to replenish the entire blood and immune system...
Genmab Announces Top-Line Interim Results For Ofatumumab In Diffuse Large B-Cell Lymphoma published
Wed, 11 Aug 2010 02:00:00 PDT
Genmab A/S (OMX: GEN) announced today top-line interim results from an initial Phase II single arm open label study of ofatumumab to evaluate the treatment of relapsed Diffuse Large B-Cell Lymphoma (DLBCL) in patients ineligible for or relapsed following a stem cell transplant...
Familial Link In Rare Childhood Leukemia published
Tue, 10 Aug 2010 02:00:00 PDT
A UCSF-led team has discovered a direct link between an inherited genetic mutation, a set of developmental abnormalities and a rare form of childhood leukemia called juvenile myelomonocytic leukemia, or JMML. The study demonstrates a new familial link in JMML and has significant implications, the researchers say, for improving the diagnosis and treatment of the disease...
Novartis Facebook Tool On Tasigna Presents Misleading Drug Information, Says FDA published
Sun, 08 Aug 2010 10:00:00 PDT
Novartis, the drug company that makes and sells cancer drug Tasigna, has received a letter from the FDA (Food and Drug Administration), USA, which accuses it of using a Facebook tool on the website with misleading information about Tasigna (nilotinib), used to treat a type of blood cancer called Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML,)...
FDA Approves New Indication For Tasigna published
Sat, 07 Aug 2010 01:00:00 PDT
The U.S. Food and Drug Administration approved a new indication for Tasigna (nilotinib) for the treatment of a rare blood cancer when it is first diagnosed. The cancer, called Philadelphia chromosome positive chronic phase chronic myeloid leukemia (Ph+ CP-CML), is a slowly progressing blood and bone marrow disease linked to a genetic abnormality...
YM BioSciences Announces Conclusion Of Phase I Dose-Escalation And Expansion Of Ongoing CYT387 Phase I/II Clinical Study published
Fri, 06 Aug 2010 04:00:00 PDT
YM BioSciences Inc. (NYSE Amex: YMI, TSX:YM), announced the conclusion of dose-escalation in the Phase I portion of its Phase I/II clinical trial of CYT387 at Mayo Clinic in patients with myelofibrosis. In total, 21 patients were treated in Phase I, with no voluntary withdrawals reported...
MicroRNA Molecule Increases Number Of Blood Stem Cells, May Help Improve Cancer Treatment published
Fri, 06 Aug 2010 01:00:00 PDT
Investigators have identified a new mechanism that controls the number of hematopoietic stem cells - cells that give rise to all blood and immune system cells...
Access Pharmaceuticals Furthers Clinical Development Program Of Thiarabine In Patients With Hematologic Malignancies published
Wed, 04 Aug 2010 03:00:00 PDT
Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP), announced it has initiated a Phase I/II dose-escalating study of its proprietary, anti-cancer drug, Thiarabine, a nucleoside analog for patients with hematologic malignancies (cancers of the blood)...
)
|
|
